A Phase 3 interventional study of lurasidone + (lithium or divalproex) and Placebo + (lithium or divalproex) in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 71 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-17.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.
Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 9th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 1st registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
Martin Lan · Sites in United States
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 348 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 348 across the 17 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 9 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies testing lurasidone in Bipolar Disorder that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing lurasidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: lurasidone + (lithium or divalproex)
Drug: Placebo + (lithium or divalproex)
Drug page: Lurasidone
lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
Time frame: Baseline, Week 6
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
Time frame: Baseline Week 6
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score
STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
Time frame: Baselin Week 6
5/11/2009 - 1/9/2012
| Milestone | Lurasidone | Placebo |
|---|---|---|
| Started | 183 | 165 |
| Completed | 143 | 136 |
| Not completed | 40 | 29 |
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) | -17.1 ± 0.87 | -13.5 ± 0.91 |
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression) | -1.96 ± 0.104 | -1.51 ± 0.109 |
STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score | -9.5 ± 0.78 | -7.0 ± 0.81 |
Collected over Adverse event reporting begins at time of informed consent signature and continues until patient discontinuatiion - 6 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone | — | 2/183 (1.1%) | 73/183 (39.9%) |
| Placebo | — | 2/163 (1.2%) | 51/163 (31.3%) |
| Event | Lurasidone | Placebo |
|---|---|---|
| Suicidal IdeationPsychiatric disorders | 1/183 | 1/163 |
| Femur FractureInjury, poisoning and procedural complications | 0/183 | 1/163 |
| DepressionPsychiatric disorders | 1/183 | 0/163 |
| Event | Lurasidone | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 32/183 | 18/163 |
| HeadacheNervous system disorders | 19/183 | 20/163 |
| SomnolenceNervous system disorders | 17/183 | 7/163 |
| TremorNervous system disorders | 15/183 | 7/163 |
| AkathisiaNervous system disorders | 14/183 | 7/163 |
| InsomniaPsychiatric disorders | 13/183 | 9/163 |
| DiarrheaGastrointestinal disorders | 8/183 | 11/163 |
Data for full analysis set is provided (intent-to-treat population)
| Age, Categorical(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 178 | 155 | 333 |
| >=65 years | 1 | 5 | 6 |
| Age, Continuous(years) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Mean | 41.0 ± 11.53 | 42.6 ± 11.75 | 41.7 ± 11.65 |
| Sex: Female, Male(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Female | 86 | 76 | 162 |
| Male | 93 | 85 | 178 |
| Region of Enrollment(participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| France | 8 | 8 | 16 |
| United States | 58 | 52 | 110 |
| Czech Republic | 27 | 21 | 48 |
| Poland | 9 | 6 | 15 |
| Ukraine | 11 | 12 | 23 |
| Romania | 2 | 3 | 5 |
| South Africa | 10 | 8 | 18 |
| Russian Federation | 9 | 10 | 19 |
| Germany | 2 | 4 | 6 |
| India | 43 | 37 | 80 |
The record gives a start of Apr 2009, a primary completion of Dec 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →